Arterial pulse wave velocity

1. Lonafarnib decreases arterial pulse wave velocity in humans.

   “Secondary outcomes included decreases in arterial pulse wave velocity and carotid artery echodensity and increases in skeletal rigidity and sensorineural hearing within patient subgroups.”

   Human trial2 y

   Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome

   Proceedings of the National Academy of Sciences of the United States of America·24 Sep 2012

More on Lonafarnib